July 2022 in “Journal of Investigative Dermatology” Blocking DPP4 can help activate hair growth and improve hair regeneration.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
January 2017 in “The American Pharmacists Association eBooks” January 2017 in “The American Pharmacists Association eBooks”
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
April 2018 in “Journal of Investigative Dermatology” DPP4 is important for scarring and skin regeneration, and managing its activity could improve skin healing treatments.
18 citations
,
October 2010 in “Bioorganic & Medicinal Chemistry Letters” New hybrid compound found to effectively prevent hair loss.
3 citations
,
February 2019 in “Molecular genetics and metabolism” The combination of tadalafil and finasteride improves urinary symptoms and erectile function in men with enlarged prostates.
September 2020 in “Scientific periodicals of Ukraine” "Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
September 2004 in “Inpharma Weekly” 14 citations
,
June 2011 in “Steroids” New compounds may help treat prostate issues without affecting androgen receptors.
1 citations
,
February 2023 in “Russian Journal of Bioorganic Chemistry” The new compound may be a safer alternative to finasteride for prostate protection.
April 2019 in “Journal of Investigative Dermatology” DPP4-positive fibroblasts play a major role in producing proteins that lead to skin fibrosis.
April 1992 in “Current opinion in therapeutic patents” New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.
47 citations
,
January 2003 in “Current opinion in urology” A new drug, dutasteride, is at least as effective as the older drug, finasteride, for treating enlarged prostate and may have additional uses.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
8 citations
,
March 2002 in “Archiv Der Pharmazie” The compound 4c effectively inhibits the enzyme linked to hair loss.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
February 2006 in “Inpharma Weekly”
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
December 2025 in “Molecules” DPP may help hair regrowth by improving blood vessel function under stress.
May 2007 in “Inpharma Weekly” 25 citations
,
June 2002 in “Steroids” 4-azasteroids, including finasteride, can inhibit 5α-reductase, helping treat conditions like enlarged prostate and hair loss.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” 3 citations
,
November 1998 in “PubMed”
March 2022 in “Research Square (Research Square)” 4-aminopyridine, a FDA-approved drug, speeds up skin wound healing and tissue regeneration.
April 2011 in “ChemInform” A new compound may effectively inhibit the enzyme linked to BPH and hair loss.